课题基金 / 基金详情

Diabetes, Metformin and Breast Cancer Prognosis

Diabetes, Metformin and Breast Cancer Prognosis
糖尿病、二甲双胍和乳腺癌预后
批准号:
8574417
负责人:
Juhua Luo
金额:
$41.46万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-01 至 2016-08-31

项目摘要

项目成果

Juhua Luo的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Diabetes and cancer are common diseases that have a tremendous impact on health worldwide. A number of studies have indicated that diabetes is associated with higher overall mortality in patients with breast cancer. However, it is unclear whether the higher overall mortality seen in breast cancer patients with diabetes compared to those without diabetes is related to a poorer breast cancer prognosis, to other causes such as cardiovascular disease, or to different management of breast cancer, including tumor characteristics and treatment choices. In addition, metformin, an oral drug widely used as a first-line therapy for type 2 diabetes, is also under consideration for use in non-diabetic cancer patients as an adjunctive therapy. However, there is no study examining its potential effect on cancer prognosis in a population-based setting. Answering these questions will have direct influence on diabetes management and cancer treatment to improve breast cancer outcomes for women with diabetes and is critical to inform the proper care of these patients. We will use data from the Women's Health Initiative (WHI), a large prospective cohort study, to assess influence of pre-existing diabetes (specific aim 1) and diabetes treatment, particularly metformin (specific aim 2), on prognosis of patients with breast cancer. This is the first prospective study o use a well-established cohort to address these questions. The Women's Health Initiative includes detailed and comprehensive data on demographic and psychosocial characteristics, breast cancer screening, breast cancer risk factors, diabetes medication treatments, tumor characteristics that are physician-adjudicated and coded using SEER protocols and physician-adjudicated causes of death. We expect the proposed analyses to advance understanding of whether and how pre-existing diabetes and diabetes treatment influences survival following breast cancer. In addition, the novel analyses and methods used for this study can be expanded in the future to a more comprehensive examination of other types of cancer in relation to diabetes or other co-morbidities. Additionally, this project will provide great opportunities for exposing students to research and stimulating their interests in pursuing careers in academic fields.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Diabetes, diabetes treatment and breast cancer prognosis.
糖尿病,糖尿病治疗和乳腺癌预后。
DOI: 10.1007/s10549-014-3146-9
发表时间: 2014-11
期刊: BREAST CANCER RESEARCH AND TREATMENT
影响因子: 3.8
作者: [Luo, Juhua, Virnig, Beth, Hendryx, Michael, Wen, Sijin, Chelebowski, Rowan, Chen, Chu, Rohan, Tomas, Tinker, Lesley, Wactawski-Wende, Jean, Lessin, Lawrence, Margolis, Karen]
通讯作者: Margolis, Karen
DOI: 10.1158/1055-9965.epi-16-0761
发表时间: 2017-02
期刊: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子: --
作者: [Liang X, Margolis KL, Hendryx M, Rohan TE, Groessl EJ, Thomson CA, Kroenke CH, Simon MS, Lane D, Stefanick M, Luo J]
通讯作者: Luo J
DOI: 10.1038/bjc.2016.141
发表时间: 2016-06-28
期刊: British journal of cancer
影响因子: 8.8
作者: [Luo J, Hendryx M, Qi L, Ho GY, Margolis KL]
通讯作者: Margolis KL
DOI: 10.1097/gme.0000000000001168
发表时间: 2019-01
期刊: Menopause (New York, N.Y.)
影响因子: --
作者: [Luo J, Manson JE, Hendryx M, Shadyab AH, Johnson KC, Dinh PC Jr, Going SB, Chlebowski R, Stefanick ML, Margolis KL]
通讯作者: Margolis KL
Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and lung cancer prognosis
  • 批准号:
    10318209
  • 项目类别:
  • 资助金额:
    $7.93万
  • 财政年份:
    2021
  • 负责人:
    Juhua Luo
  • 依托单位:
海外基金